Cite
HARVARD Citation
Lombardi, F. et al. (2022). Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. HIV research & clinical practice. 23 (1), pp. 28-36. [Online].